Canada Markets open in 8 hrs 46 mins

Entheon Biomedical Corp. (ENTBF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0226-0.0005 (-2.38%)
At close: 11:59AM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.0232
Open0.0237
BidN/A x N/A
AskN/A x N/A
Day's Range0.0226 - 0.0237
52 Week Range0.0100 - 0.1180
Volume15,001
Avg. Volume11,011
Market Cap1.335M
Beta (5Y Monthly)1.89
PE Ratio (TTM)N/A
EPS (TTM)-0.1690
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Ehave Shareholder from CEO Ben Kaplan and Corporate Update

    MIAMI, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a Healthcare Analytics provider with interests in the psychedelic and mental health sectors, today issued a letter to shareholders from its Chief Executive Officer, Ben Kaplan. Dear Fellow Shareholders As 2022 draws to a close, many of us will reflect on a year that saw global economic activity experiencing a broad-based and sharper-than-expected slowdown, increased inflation higher than we have seen in seve

  • Newsfile

    Entheon Announces Closing of Previously Announced Sale of Certain DMT Clinical Assets

    Vancouver, British Columbia--(Newsfile Corp. - July 11, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company") today announced that, further to its news release dated June 7, 2022, it has completed the sale of its Phase 1 N,N-dimethyltryptamine ("DMT") study (the "DMT Study") to Cybin IRL Limited (the "Purchaser"), a subsidiary of Cybin Inc. pursuant to an asset purchase agreement for a purchase price of CAD$1,000,000 (the "Transaction"). ...

  • Newsfile

    Entheon Announces Sale of Certain DMT Clinical Assets and Filing of Provisional Novel Compound Patents

    Vancouver, British Columbia--(Newsfile Corp. - June 7, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company") today announced that it has entered into a definitive agreement (the "Agreement") dated June 7, 2022 with Cybin IRL Limited (the "Purchaser"), a subsidiary of Cybin Inc. ("Cybin"), pursuant to which the Company has agreed to sell its Phase 1 N,N-dimethyltryptamine ("DMT") study (the "DMT Study") to the Purchaser (the "Transaction") for ...